New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|December 18, 2018
Benefit With Cemiplimab in Patients With mCSCC
Author(s)Danny Rischin, MD, MBBS, FRACP
Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Advertisement
Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, shares his insights on cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).
Advertisement
Related to this article
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
2
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5